« Back to Record
Citation APA

Cardoso, F., Durbecq, V., Laes, J.-F., Badran, B., Lagneaux, L., Bex, F., Desmedt, C., Willard-Gallo, K., Ross, J. S., Burny, A., Piccart-Gebhart, M., & Sotiriou, C. (2006). Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Molecular cancer therapeutics, 5(12), 3042-3051. doi:10.1158/1535-7163.MCT-06-0104


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/53070

Cardoso, F., Durbecq, V., Laes, J.-F., Badran, B., Lagneaux, L., Bex, F., Desmedt, C., Willard-Gallo, K., Ross, J. S., Burny, A., Piccart-Gebhart, M., & Sotiriou, C. (2006). Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Molecular cancer therapeutics, 5(12), 3042-3051. doi:10.1158/1535-7163.MCT-06-0104